Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Deep learning-based reconstruction for 5.0T magnetic resonance imaging (MRI) in nasopharyngeal carcinoma: comparison of image quality and diagnostic efficacy.

Clinical radiology·2026

Same author

[Combining clinical and pathological features to explore the diagnostic challenges of marginal zone lymphoma].

Zhonghua yi xue za zhi·2026

Same author

[A case of EGPA with eosinophilic otitis media as the prominent symptom].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2026

Same author

[Analysis of 3-year postoperative prognosis and influencing factors in patients with H3 K27-altered diffuse midline glioma].

Zhonghua yi xue za zhi·2026

Same author

[A study on the application of an edge-enhanced triple-branch neural network in three-dimensional segmentation of the condyle].

Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology·2026

Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026

Same journal

Restoration of oxidative stress by HNF4α deletion in VWA8-null hepatocytes.

Biochemistry and biophysics reports·2026

Same journal

Intranasal administration of Aloe-derived nanovesicles attenuates early radiation-induced lung injury.

Biochemistry and biophysics reports·2026

Same journal

A glycosaminoglycan microarray identifies galectin-4 binding to sulfated glycosaminoglycans.

Biochemistry and biophysics reports·2026

Same journal

The role of SUMOylation in regulating proteins that drive neuronal disease progression.

Biochemistry and biophysics reports·2026

Same journal

Plant-derived extracellular vesicles as bioactive nanoplatforms: Biogenesis, therapeutic evidence, and translational challenges.

Biochemistry and biophysics reports·2026

Same journal

Effects of metformin and exercise on Alzheimer's model induced by D-galactose in the rats: A behavioral, histological and BDNF gene study.

Biochemistry and biophysics reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 12, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells.

P Zhou¹, X Ma¹, S Scalia¹

¹Tufts Medicine Myeloma and Amyloid Program, USA.

Biochemistry and Biophysics Reports

|May 7, 2025

Summary

This summary is machine-generated.

Heterohybridoma (HH) technology successfully produced human light chain (FLC) producing clones from multiple myeloma and polyclonal gammopathy patients. These FLC-producing HH clones offer valuable tools for studying FLC behavior and developing new therapeutics.

Keywords:

CD138 Heterohybridomas Immunoglobulin light chains Plasma cells

More Related Videos

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Experiment Videos

Last Updated: May 12, 2025

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Area of Science:

Immunology
Biotechnology

Background:

Mammalian cell lines for human light chain (FLC) production are scarce, hindering research.
Heterohybridoma (HH) technology offers a novel approach to generate these essential tools.

Purpose of the Study:

To develop and characterize heterohybridoma (HH) clones capable of producing human light chains (FLC).
To provide valuable tools for studying FLC behavior, metabolism, and therapeutic targeting.

Main Methods:

Selected CD138+ cells from multiple myeloma (MM) and polyclonal gammopathy (PG) patients.
Fused selected cells with B5-6 T cells and cultured using hypoxanthine-aminopterin-thymidine (HAT) medium.
Selected and characterized HH clones using ELISA, flow cytometry, and RT-PCR for FLC production, intracellular levels, and gene sequencing.

Main Results:

Successfully generated FLC-producing HH clones from 50% of MM and PG cases.
HH clones demonstrated robust intracellular FLC production (median 9849 MFI) and secretion (median 47 μg/mL in vitro, 66.4 μg/mL in vivo).
Observed dimer/monomer ratios in vitro and in vivo, with increased dimer formation in vivo.

Conclusions:

Heterohybridoma (HH) technology is effective for producing human light chain (FLC) secreting clones.
Generated HH clones provide a platform for studying FLC metabolism and evaluating FLC-targeting therapeutics.
Further research can utilize these HH clones to investigate FLC-related diseases and develop novel treatment strategies.